Skip to Content

Edesa Biotech Inc EDSA

Morningstar Rating
$4.38 −0.09 (1.90%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

EDSA is trading at a 792% premium.
Price
$4.33
Fair Value
$78.95
Uncertainty
Extreme
1-Star Price
$75.94
5-Star Price
$3.68
Economic Moat
Nwxv
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if EDSA is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$4.47
Day Range
$4.214.73
52-Week Range
$2.468.33
Bid/Ask
$4.32 / $4.84
Market Cap
$14.09 Mil
Volume/Avg
14,283 / 8,280

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB01, is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis. The company operates in a single segment: research and development, manufacturing, and commercialization of innovative pharmaceutical products. The company's EB05 candidate is a monoclonal antibody therapy for hospitalized COVID-19 patients.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
16

Valuation

Metric
EDSA
Price/Earnings (Normalized)
Price/Book Value
3.32
Price/Sales
Price/Cash Flow
Price/Earnings
EDSA

Financial Strength

Metric
EDSA
Quick Ratio
1.82
Current Ratio
1.97
Interest Coverage
Quick Ratio
EDSA

Profitability

Metric
EDSA
Return on Assets (Normalized)
−77.03%
Return on Equity (Normalized)
−97.88%
Return on Invested Capital (Normalized)
−98.78%
Return on Assets
EDSA
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRCfqykqwrQlwt$599.5 Bil
VRTX
Vertex Pharmaceuticals IncVwgtfryGyykf$117.9 Bil
REGN
Regeneron Pharmaceuticals IncLpjybkbvKtgklr$108.5 Bil
MRNA
Moderna IncDphbdvtmSqk$63.9 Bil
BNTX
BioNTech SE ADRQsvvnrdQtfs$23.4 Bil
ARGX
argenx SE ADRQhjfffvCtg$21.7 Bil
ALNY
Alnylam Pharmaceuticals IncWykbtnxGsbkkh$18.7 Bil
BMRN
Biomarin Pharmaceutical IncWjmgpyvrLhgmtl$14.3 Bil
INCY
Incyte CorpTznscypxBjbcr$12.9 Bil
UTHR
United Therapeutics CorpDzpqqctsFls$12.1 Bil

Sponsor Center